Introduction

Leprosy is one of humanity’s oldest diseases, yet its story is far from over. Despite decades of progress, new cases emerge yearly, mainly in regions marked by poverty and social exclusion. Understanding the global epidemiology of leprosy is crucial for public health, social justice, and the preservation of the dignity of those affected.

What is leprosy?

Leprosy is a chronic infectious disease caused by Mycobacterium leprae. It primarily affects the skin, peripheral nerves, mucosa of the upper respiratory tract, and eyes. If untreated, it can cause progressive and permanent disabilities, especially in the hands, feet, and face.

Key facts

Curable: 

Leprosy is curable with multidrug therapy (MDT), which has been provided free of charge worldwide since 1995.

Transmission: 

The disease is transmitted through droplets from the nose and mouth during close and frequent contact with untreated cases.

Stigma: 

Beyond physical symptoms, leprosy often leads to social stigma, isolation, and discrimination, affecting mental health and quality of life.

How is leprosy spread and diagnosed?

Leprosy is not highly contagious. Transmission occurs through prolonged, close contact with an untreated person, usually via respiratory droplets. The disease does not spread through casual contact such as shaking hands or sharing meals.

Diagnosis

Clinical signs: 

Diagnosis is mainly clinical, based on:

• Loss of sensation in pale or reddish skin patches
• Thickened or enlarged peripheral nerves
• Microscopic detection of bacilli in skin smears

Classification: 

Cases are classified as:

• Paucibacillary (PB): 

Fewer bacteria, milder symptoms

• Multibacillary (MB): 

More bacteria, a higher risk of complications

Global trends: Incidence, prevalence, and decline

Historical perspective

Leprosy has been known since ancient times. The introduction of MDT in the 1980s revolutionised treatment and led to a dramatic drop in global cases.

Recent data

Annual new cases: 

Around 200,000 new cases are reported yearly, with a steady global decline.

Prevalence:

In 2019, the global prevalence was 6.43 per 100,000 people, down from 17 per 100,000 in 1990.

Gender and age: 

Incidence is higher in males than in females and peaks in adults aged 25–35.

Socio-Demographic Index (SDI): 

The burden is highest in countries with low SDI, reflecting poverty and inequality.

Decline in numbers

Global incidence rate: 

Fell from 1.48 per 100,000 in 1990 to 0.65 per 100,000 in 2019.

Prevalence rate: 

Dropped from 17 to 6.43 per 100,000 in the same period.

Disability-Adjusted Life Years (DALY): 

Also decreased, indicating fewer people living with leprosy-related disability.

Current hotspots and regional patterns

Where is leprosy most common today?

India: 

Accounts for over half of all new cases worldwide, about 107,000 cases in 2023.

Brazil and Indonesia: 

Each reports more than 10,000 new cases annually.

Other countries: 

Bangladesh, the Democratic Republic of the Congo, Ethiopia, Madagascar, Mozambique, Myanmar, Nepal, Nigeria, Philippines, Somalia, Sri Lanka, and Tanzania each report 1,000–10,000 new cases annually.

Pacific islands: 

Micronesia, Kiribati, and the Marshall Islands have the highest incidence rates per capita.

Regional trends

South Asia and tropical Latin America: 

Highest age-standardised incidence and prevalence rates.

Africa: 

Central and Eastern Sub-Saharan Africa remain significant hotspots.

Oceania: 

Some Pacific islands continue to have high rates, though numbers are small in absolute terms.

Progress and challenges

Countries with zero cases: 

Fifty-six countries reported zero new cases in 2023, and 112 reported fewer than 1,000 new cases.

Persistent hotspots: 

High-burden regions often overlap with poverty, limited healthcare, and social exclusion areas.

Leprosy and social determinants: Poverty, inequality, and stigma

The poverty connection

Leprosy is often called a “disease of poverty.” It thrives in communities with poor housing, overcrowding, inadequate nutrition, and limited access to healthcare services. Studies show a strong link between leprosy and low socio-economic status, as well as income inequality.

Stigma and discrimination

Social exclusion: 

People affected by leprosy often face exclusion from community life, employment, education, and even their own families.

Gender disparities: 

Women and girls with leprosy may experience “triple discrimination” due to gender, disease, and disability.

Mental health: 

The psychological impact of stigma can be severe, leading to depression, anxiety, and even suicide attempts.

Healthcare barriers: 

Stigma can delay diagnosis and treatment, increasing the risk of disability and community transmission.

Laws and human rights

In some countries, outdated laws still discriminate against people affected by leprosy, restricting their rights to marry, work, or participate in society. Global initiatives are working to change these laws and promote inclusion.

Prevention, treatment, and innovations

Treatment

Multidrug Therapy (MDT): 

The standard regimen includes dapsone, rifampicin, and clofazimine. PB cases are treated for 6 months; MB cases for 12 months.

Free access: 

The WHO provides MDT free of charge, with support from partners like the Nippon Foundation and Novartis.

Early diagnosis: 

Prompt treatment prevents disability and stops transmission.

Prevention

Contact tracing:

Identifying and monitoring close contacts of new cases is vital for breaking the chain of transmission.

Post-Exposure Prophylaxis (PEP): 

A single dose of rifampicin (SDR-PEP) given to contacts of leprosy patients can reduce their risk of developing the disease.

Vaccination: 

The BCG vaccine, widely used against tuberculosis, also offers some protection against leprosy, especially in children.

Innovations

Screening tests: 

New tools can detect leprosy at a subclinical stage, allowing for earlier intervention.

Community engagement: 

The key to successful control is integrating health education, stigma reduction programs, and socio-economic rehabilitation.

Challenges to elimination

Ongoing transmission

Despite global progress, new cases continue to emerge, especially in children, a sign of ongoing transmission in the community. Delayed diagnosis and treatment, particularly due to stigma, remain significant obstacles to effective care.

Drug resistance and relapse

Drug resistance: 

Occasional cases of resistance to MDT drugs have been reported, though they remain rare.

Relapse: 

Some patients experience relapse after treatment, requiring careful monitoring and follow-up.

COVID-19 Impact

The COVID-19 pandemic disrupted health services worldwide, leading to a temporary drop in leprosy case detection but likely increasing undiagnosed cases and future disability.

Funding and expertise

As leprosy becomes less common, funding and expertise for control programs may decline, risking setbacks in the fight against the disease.

The human side: Stories and impact

Leprosy is not just a medical condition—it’s a profoundly human experience. People affected by leprosy often face a double burden: the physical effects of the disease and the social consequences of stigma and exclusion.

Real-world impact

Delayed diagnosis: 

Many people hide their symptoms out of fear, leading to late diagnosis and permanent disability.

Social isolation: 

Stigma can lead to loss of employment, exclusion from community life, and even family rejection.

Mental health: 

The psychological toll can be profound, with high rates of depression, anxiety, and suicidal thoughts among those affected.

Resilience and advocacy: 

Many individuals and organisations are fighting back, sharing their stories, advocating for rights, and supporting others on the path to healing and inclusion.

FAQs

Q1: Is leprosy still a problem in the modern world?

Yes. While rare in high-income countries, leprosy remains a public health challenge in over 120 countries, with about 200,000 new cases each year.

Q2: Can leprosy be cured?

Absolutely. Leprosy is curable with multidrug therapy (MDT), which is provided free of charge worldwide.

Q3: How is leprosy transmitted?

Leprosy spreads through prolonged, close contact with an untreated person, mainly via respiratory droplets. It is not highly contagious and does not spread through casual contact.

Q4: Who is most at risk?

People living in poverty, in overcrowded conditions, or with limited access to healthcare are at the highest risk. Children in endemic areas are also vulnerable.

Q5: What are the main challenges to eliminating leprosy?

Ongoing transmission in hotspots, delayed diagnosis due to stigma, occasional drug resistance, and declining funding/expertise are key challenges.

Q6: What is being done to fight leprosy?

Efforts include early diagnosis, free MDT, contact tracing, post-exposure prophylaxis, community education, and programs to reduce stigma and promote inclusion.

Summary

Leprosy is a curable disease that continues to affect hundreds of thousands of people worldwide, mainly in regions marked by poverty, limited healthcare, and social stigma. While global incidence and prevalence have declined dramatically, persistent hotspots remain in South Asia, parts of Africa, and the Pacific. The fight against leprosy is not just a medical endeavour—it’s also a social one, requiring proactive efforts to reduce stigma, promote inclusion, and address the root causes of poverty and inequality. A leprosy-free world is within reach with continued commitment, innovation, and compassion.